U.S. markets closed
  • S&P 500

    3,841.94
    +73.47 (+1.95%)
     
  • Dow 30

    31,496.30
    +572.16 (+1.85%)
     
  • Nasdaq

    12,920.15
    +196.68 (+1.55%)
     
  • Russell 2000

    2,192.21
    +45.29 (+2.11%)
     
  • Crude Oil

    66.28
    +2.45 (+3.84%)
     
  • Gold

    1,698.20
    -2.50 (-0.15%)
     
  • Silver

    25.30
    -0.17 (-0.65%)
     
  • EUR/USD

    1.1925
    -0.0054 (-0.45%)
     
  • 10-Yr Bond

    1.5540
    +0.0040 (+0.26%)
     
  • GBP/USD

    1.3827
    -0.0067 (-0.48%)
     
  • USD/JPY

    108.2450
    +0.2690 (+0.25%)
     
  • BTC-USD

    47,856.11
    +495.20 (+1.05%)
     
  • CMC Crypto 200

    982.93
    +39.75 (+4.21%)
     
  • FTSE 100

    6,630.52
    -20.36 (-0.31%)
     
  • Nikkei 225

    28,864.32
    -65.78 (-0.23%)
     

Alkermes: Q2 Earnings Insights

  • Oops!
    Something went wrong.
    Please try again later.
Benzinga Insights
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.

Shares of Alkermes (NASDAQ:ALKS) rose 2.5% in pre-market trading after the company reported Q2 results.

Quarterly Results

Earnings per share decreased 33.33% year over year to $0.06, which beat the estimate of ($0.01).

Revenue of $247,529,000 decreased by 11.56% from the same period last year, which beat the estimate of $232,750,000.

Outlook

The upcoming fiscal year's EPS expected to be between $0.00 and $0.19.

The upcoming fiscal year's revenue expected to be between $965,000,000 and $1,005,000,000.

How To Listen To The Conference Call

Date: Jul 29, 2020

View more earnings on ALKS

Time: 08:00 AM

ET Webcast URL: https://edge.media-server.com/mmc/p/vx5ij3ka

Recent Stock Performance

52-week high: $23.50

Company's 52-week low was at $11.98

Price action over last quarter: Up 47.19%

Company Description

Alkermes PLC is a fully integrated global biotechnology company that applies its proprietary technologies to research, develop, and commercialize pharmaceutical products designed for unmet medical needs in major therapeutic areas. The company utilizes several collaborative arrangements to develop and commercialize products and, in so doing, to access technological, financial, marketing, manufacturing, and other resources. Alkermes either purchases active drug products from third parties or receives them from its third-party licensees to formulate products using its technologies.

See more from Benzinga

© 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.